NASDAQ:IMMU - Immunomedics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immunomedics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.14 +0.11 (+0.61 %) (As of 02/21/2020 11:26 AM ET) Add Compare Today's Range$17.76Now: $18.14▼$18.1850-Day Range$18.06MA: $19.12▼$21.1652-Week Range$11.59Now: $18.14▼$22.22Volume49,909 shsAverage Volume1.16 million shsMarket Capitalization$3.51 billionP/E RatioN/ADividend YieldN/ABeta2.3 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMMU Previous Symbol CUSIP45290710 CIK722830 Webhttp://www.immunomedics.com/ Phone973-605-8200Debt Debt-to-Equity Ratio0.30 Current Ratio6.51 Quick Ratio6.51Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.16 million Price / Sales1,623.78 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Net Income$-273,840,000.00 Net MarginsN/A Return on Equity-329.61% Return on Assets-76.70%Miscellaneous Employees346 Outstanding Shares193,350,000Market Cap$3.51 billion Next Earnings Date2/27/2020 (Confirmed) OptionableOptionable Receive IMMU News and Ratings via Email Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:IMMU Rates by TradingView Immunomedics (NASDAQ:IMMU) Frequently Asked Questions What is Immunomedics' stock symbol? Immunomedics trades on the NASDAQ under the ticker symbol "IMMU." How were Immunomedics' earnings last quarter? Immunomedics, Inc. (NASDAQ:IMMU) issued its quarterly earnings data on Wednesday, October, 30th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.09. During the same period in the prior year, the company earned ($0.34) earnings per share. View Immunomedics' Earnings History. When is Immunomedics' next earnings date? Immunomedics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Immunomedics. What price target have analysts set for IMMU? 9 Wall Street analysts have issued 12 month price targets for Immunomedics' stock. Their forecasts range from $16.00 to $40.00. On average, they anticipate Immunomedics' stock price to reach $27.33 in the next twelve months. This suggests a possible upside of 50.7% from the stock's current price. View Analyst Price Targets for Immunomedics. What is the consensus analysts' recommendation for Immunomedics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics. What are Wall Street analysts saying about Immunomedics stock? Here are some recent quotes from research analysts about Immunomedics stock: 1. HC Wainwright analysts commented, "We remind investors that sacituzumab previously achieved a 31% 6.8-month median progression-free survival (mPFS) which, in our view, compares favorably to chemotherapy’s effect in this patient population (10-13% ORR and 3-4 month mPFS). Accordingly, we reiterate our Buy rating, while reducing our 12-month price target from $28 to $26 to account for the removal of the second- line HR+, HER2- mBC setting from our assumptions. IMMU-132 filing resubmission remains on track for early 4Q19." (8/8/2019) 2. According to Zacks Investment Research, "Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. " (7/16/2019) Has Immunomedics been receiving favorable news coverage? Media stories about IMMU stock have trended negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immunomedics earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Immunomedics. Who are some of Immunomedics' key competitors? Some companies that are related to Immunomedics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Immunomedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Celgene (CELG), Synergy Pharmaceuticals (SGYP), Seattle Genetics (SGEN), NVIDIA (NVDA), ImmunoGen (IMGN), Exelixis (EXEL), Micron Technology (MU), Iovance Biotherapeutics (IOVA), Netflix (NFLX) and ACADIA Pharmaceuticals (ACAD). Who are Immunomedics' key executives? Immunomedics' management team includes the folowing people: Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)Mr. Scott A. Canute MBA, Exec. Director (Age 58)Mr. Brendan Delaney, Chief Commercial Officer (Age 44)Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52) Who are Immunomedics' major shareholders? Immunomedics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Boxer Capital LLC (4.37%), State Street Corp (3.51%), ArrowMark Colorado Holdings LLC (2.79%), FMR LLC (2.39%), Janus Henderson Group PLC (1.92%) and Jennison Associates LLC (1.56%). Company insiders that own Immunomedics stock include Avoro Capital Advisors Llc, Bryan Ball, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics. Which institutional investors are selling Immunomedics stock? IMMU stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Asset Management Americas Inc., Pictet Asset Management Ltd., Janus Henderson Group PLC, UBS Group AG, Sectoral Asset Management Inc, Marshall Wace LLP and Peregrine Capital Management LLC. View Insider Buying and Selling for Immunomedics. Which institutional investors are buying Immunomedics stock? IMMU stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Partner Fund Management L.P., Boxer Capital LLC, Franklin Resources Inc., Goldman Sachs Group Inc., Fiera Capital Corp and Renaissance Technologies LLC. Company insiders that have bought Immunomedics stock in the last two years include Avoro Capital Advisors Llc, Bryan Ball and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics. How do I buy shares of Immunomedics? Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Immunomedics' stock price today? One share of IMMU stock can currently be purchased for approximately $18.14. How big of a company is Immunomedics? Immunomedics has a market capitalization of $3.51 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,840,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 346 workers across the globe.View Additional Information About Immunomedics. What is Immunomedics' official website? The official website for Immunomedics is http://www.immunomedics.com/. How can I contact Immunomedics? Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected] MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 401 (Vote Outperform)Underperform Votes: 417 (Vote Underperform)Total Votes: 818MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2020 by MarketBeat.com StaffFeatured Article: What is diluted earnings per share (Diluted EPS)?
